To sum up, our research demonstrated that ARMS-Plus possessed a high sensitive and specificity for the detection of EGFR activating mutations in advanced NSCLC patients, with a diagnostic performance comparable to that of ddPCR. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.